![Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/cd09204c-9b48-40a0-8150-668da0b7de95/egi1097ZWVN78V.jpg)
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS
![PDF) Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer PDF) Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer](https://www.researchgate.net/publication/309016143/figure/fig1/AS:416393016168449@1476287239598/CDK4-CDK6-inhibitors-mechanism-of-action-Notes-in-eR-ve-HeR2-ve-breast-cancer-oncogenic_Q320.jpg)
PDF) Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer
![Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases - Annals of Oncology Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b259f3d7-fe34-4cf3-8491-407b8ed35004/gr1.jpg)
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases - Annals of Oncology
![Early PIK3CA ctDNA dynamics predict progression-free survival (PFS) on... | Download Scientific Diagram Early PIK3CA ctDNA dynamics predict progression-free survival (PFS) on... | Download Scientific Diagram](https://www.researchgate.net/publication/323494109/figure/fig4/AS:631636504875064@1527605286519/Early-PIK3CA-ctDNA-dynamics-predict-progression-free-survival-PFS-on-palbociclib-and_Q320.jpg)
Early PIK3CA ctDNA dynamics predict progression-free survival (PFS) on... | Download Scientific Diagram
![Ibrance (Palbociclib Capsules for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning Ibrance (Palbociclib Capsules for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning](https://images.rxlist.com/images/rxlist/ibrance2.gif)
Ibrance (Palbociclib Capsules for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning
![The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ... The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2029521588/2047295717/gr4.jpg)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...
![Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial - Annals of Oncology Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/61e7a08b-c2ed-455e-86a1-18ed4f559542/gr1.jpg)
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial - Annals of Oncology
![NEJM on Twitter: "Original Article: Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer https://t.co/PoifcpQnQc… https://t.co/QAIzDYP8hl" NEJM on Twitter: "Original Article: Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer https://t.co/PoifcpQnQc… https://t.co/QAIzDYP8hl"](https://pbs.twimg.com/media/DsPVYHzWwAA9od0.jpg)
NEJM on Twitter: "Original Article: Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer https://t.co/PoifcpQnQc… https://t.co/QAIzDYP8hl"
![Ibrance (Palbociclib Capsules for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning Ibrance (Palbociclib Capsules for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning](https://images.rxlist.com/images/rxlist/ibrance3.gif)
Ibrance (Palbociclib Capsules for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning
![Early PIK3CA ctDNA dynamics predict progression-free survival (PFS) on... | Download Scientific Diagram Early PIK3CA ctDNA dynamics predict progression-free survival (PFS) on... | Download Scientific Diagram](https://www.researchgate.net/publication/323494109/figure/fig4/AS:631636504875064@1527605286519/Early-PIK3CA-ctDNA-dynamics-predict-progression-free-survival-PFS-on-palbociclib-and.png)
Early PIK3CA ctDNA dynamics predict progression-free survival (PFS) on... | Download Scientific Diagram
![Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-05755-7/MediaObjects/10549_2020_5755_Fig2_HTML.png)